Auszug aktueller Veröffentlichungen

2019:

1. R. A. Werner, H. Ilhan, S. Lehner, L. Papp, N. Zsótér, I. Schatka, D. O. Muegge, M. S. Javadi, T. Higuchi, A. K. Buck, P. Bartenstein, F. Bengel, M. Essler C. Lapa, R. A. Bundschuh: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol. Imaging Biol., 21(3):582-590, 2019.

 

2. L. Thomas, T. Schultz, V. Prokic, M. Guckenberger, S. Tanadini-Lang, M. Hohberg, M. Wild, A. Drzezga, R. A. Bundschuh: 4D-CT-based motion correction of PET images using 3D iterative deconvolution. Oncotarget, 10(31):2987-2995, 2019.

 

3. T.S. Plum, B. Kreppel, E. Eppard, M. Meisenheimer, H. Strunk, R. A. Bundschuh, J.-P. Sinnes, F. Rösch, M. Essler, F. C. Gaertner: Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours. Mol. Imaging Biol., [Epub ahead of print].

 

4. A. Khawar, E. Eppard, F. Roesch, H. Ahmadzadehfar, S. Kürpig, M. Meisenheimer, F. C. Gaertner, M. Essler, R. A. Bundschuh: Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: A new zolendronate-based bisphosphonate for PET/CT diagnosis of bone diseases. Ann. Nucl. Med., 33(6):404-4013, 2019.

 

5. R. A. Werner, R. A. Bundschuh, L. Bundschuh, C. Lapa, Y. Yin, M. S. Javadi, A. K. Buck, T. Higuchi, K. J. Pienta, M. G. Pomper, M. A. Lodge, M. A. Gorin, S. P. Rowe: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyl: Impact of Tumor Burden on Normal Organ Uptake. Mol. Imaging. Biol., 2019 doi: 10.1007/s11307-019-01375-w. [Epub ahead of print]

 

6. K. Sahakyan, X. Li, M. A. Lodge, R. A. Werner, R. A. Bundschuh, L. Bundschuh, H. R. Schuchardt, R. P. Baum, K. J. Pienta, M. G. Pomper, A. E. Ross, M. A. Gorin, S. P. Rowe: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyl: Intrapatient and Interpatient Variability of Normal Organ Uptake. Mol Imaging Biol. 2019 doi: 10.1007/s11307-019-01376-9. [Epub ahead of print]

 

7. C. Scholl, R. A. Bundschuh, S. E. Hirzebruch, T. Glanert, X. Wie, S. Kürpig, R. Rödel, M. Essler, L. Thomas, H. Ahmadzadehfar: Radionuclide intake risk in the clinical administration of 223RaCl2. J. Radiol. Prot., 39(2):387-398, 2019.

 

8. R. A. Werner*, R. A. Bundschuh*, T. Higuchu, M. S. Javadi, S. P. Rowe, N. Zsótér, M. Kroiss, M. Fassnacht, A. K. Buck, M. C. Kreissl, C. Lapa: Volumetric and Texture Analysis of Pretherapeutic 18F-FDG PET can Predict Overall Survival in Medullary Thyroid Cancer Patients Treated with Vandetanib. Endocrine, 63(2):293-300, 2018.

 

*both authors contributed in equal to the manuscript

 

 

2018:

1. L. Schwarte, L. Thomas, E. Eppard, M. Meisenheimer, C. Weiss-Wichert, R. Fimmers, N. Zsóter, H. Strunk, M. Essler, R. A. Bundschuh: Comparison of Tumor Heterogeneity Assessed with Textural Parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in Patients with Metastatic Prostate Cancer. Biomed J. Sci. & Tech. Res., 11(5), 2018.

 

2. R. A. Werner, R. A. Bundschuh, L. Bundschuh, M. S. Javadi, J. P. Leal, T. Higuchi, K. J. Pienta, A. K. Buck, M. G. Pomper, M. A. Gorin, C. Lapa, S. P. Rowe: Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging. J. Nucl. Med., 59(12):1857-1864, 2018.

 

3. Z. Khurshid, H. Ahmadzadefar, Florian C. Gaertner, L. Papp, N. Zsóter, M. Essler, R. A. Bundschuh: Role of Textural Heterogeneity Parameters in Patient Selection for Lu-177 PSMA Therapy via Response Prediction. Oncotarget, 9(70):33312-33321, 2018.

 

4. A. Khawar, E. Eppard, J. P. Sinnes, F. Roesch, H. Ahmadzadefar, S. Kürpig, M. Meisenheimer, F. C. Gaertner, M. Essler, R. A. Bundschuh: Prediction of normal organ absorbed doses for [177Lu]Lu-PSMA-617 using [44Sc]Sc-PSMA-617 pharmacokinetics in metastatic castration resistant prostate carcinoma (mCRPC) patients. Clin Nucl Med, 43(7):486-491, 2018.

  

5. A. Khawar E. Eppard, J. P. Sinnes, F. Roesch, H. Ahmadzadefar, S. Kürpig, M. Meisenheimer, F. C. Gaertner, M. Essler, R. A. Bundschuh: [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastasic Castration-Resistant Prostate Carcinoma. Clin. Nucl. Med., 43(5):323-330, 2018.

 

6. L. Thomas, S. Kantz, A. Hung, D. Monaco, F. C. Gaertner, M. Essler, H. Strunk, W. Laub, R. A. Bundschuh: 68Ga-PSMA-PET/CT Imaging of Localized Primary Prostate Cancer Patients for Intensity Modulated Radiation Therapy Treatment Planning with Integrated Boost. Europ. J. Nucl. Med. Mol. Imaging, 45(7):1170-1178, 2018.

 

7. Y. Tolkach*, H. Gevensleben*, R. A. Bundschuh*, A. Koyun, D. Huber, C. Kehrer, T. Hecking, M.-D. Keyver-Paik, C. Kaiser, H. Ahmadzadefar, M. Essler, W. Kuhn, G. Kristiansen: Prostate-Specific Membran Antigen in Breast Cancer: A Comprehensive Evaluation of Expression and a Case Report of Radionuclide Therapy. Breast Cancer Res. Treat., 169(3):447-455, 2018.

*both authors contributed in equal to the manuscript

 

8. S. Spatz, Y. Tolkach, K. Jung, C. Stephan, J. Busch, B. Ralla, A. Rabien, G. Feldmann, P. Brossart, R. A. Bundschuh, H. Ahmadzadefar, M. Essler, M. Toma, S. C. Müller, J. Ellinger, S. Hauser, G. Kristiansen: Comprehensive Evaluation of Prostate-Specific Membran Antigen  Expression in the Vasculature of Renal Tumors: Implication for Imaging Studies and Prognostic Role. J. Urol., 199(2):370-377, 2018.

 

 

 

2017:

1. E. Eppard, A. de la Fuente, A. Benesova, A. Khawar, R. A. Bundschuh, F. C. Gärtner, B. Kreppel, K. Kopka, M. Essler, F. Rösch: Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics, 7(18):4359-4369, 2017.

 

2. L. Thomas, C. Balmus, H. Ahmadzadehfar, M. Essler, H. Strunk, R. A. Bundschuh: Assessment of Bone Metastases in Patients with Prostate Cancer – A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT. Pharmaceuticals, 10(3), 2017.

 

3. F. C. Gaertner, K. Halabi, H. Ahmadzadehfar, S. Kürpig, E. Eppard, C. Kotsikopoulos, N. Liakos, R. A. Bundschuh, H. Strunk, M. Essler: Uptake of PSMA-ligands in normal tissue is dependent on Tumor Load in Patients with Prostate Cancer. Oncotarget, 8(33):55094-55103, 2017.

 

4. S. Kebir, Z. Kurshid, F. C. Gaertner, M. Essler, E. Hattingen, R. Fimmers, B. Scheffler, U. Herrlinger, R. A. Bundschuh*, M. Glas*: Unsupervised Consensus Cluster Analysis of [18F]-fluorethyl-L-tyrosine Positron Emission Tomography Identified Textural Features for the Diagnosis of Pseudoprogression in High-Grade Glioma. Oncotarget, 8(5): 8294-8304, 2017.

*both authors contributed in equal to the manuscript

 

 

5. R. A. Werner, C. Lapa, H. Ilhan, T. Higuchi, A. K. Buck, S. Lehner, P. Bartenstein, F. Bengel, I. Schatka, D. O. Muegge, L. Papp, N. Zsóter, T. Große-Ophoff, M. Essler, R. A. Bundschuh: Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget, 8(4):7039-7049, 2017. 

 

 

2016:

1. S. Kebir, L. Rauschenbach, N. Galldiks, M. Schlaak, E. Hattingen, J. Landsberg, R. A.

Bundschuh, K.-J. Langen, B. Scheffler, U. Herrlinger, M. Glas: Dynamic O-(2-[18F]fluoroethyl)-

L-tyrosine PET Imaging fort he Detection of Checkpoint Inhibitor-Related Pseudoprogression in

Melanoma Brain Metastases. Neuro Oncology, 18(10): 1462-1464, 2016.

 

2.      D. Fecher, E. C. Hofmann, A. K. Buck, R. A. Bundschuh, S. Nietzer, G. Dandekar, T.

Walles, H. Walles, K. Lückerath, M. Steinke: Human Organotypic Lung Tumor Models: Suitable

For Preclinical 18F-FDG PET-Imaging. PloS One, 11(8): e0160282, 2016.

 

3.      J. P. Michelis, J. Zimmermann, J. R. Bedarf, R. A. Bundschuh, F. C. Gaertner: Facial

Movement Disorder and Dopamine Imaging in a Patient with Amphetamine Abuse. J. Park Rel

Dis, 2016. [Epub DOI: 10.1016/j.parkreldis.2016.07.020].

 

4.      R. A. Werner, M. Kroiss, M. Nakajo, D. O. Mügge, S. Hahner, M. Fassnacht, A. Schirbel, C.

Bluemel, T. Higuchi, L. Papp, N. Zsótér, A. K. Buck, R. A. Bundschuh*, C. Lapa: Assessment

of Tumor Heterogeneity in Treatment-naive Adrenocortical Cancer Patients Using 18F-FDG

Positron Emission Tomography. Endocrine, 53(3): 791-800, 2016. 

 

5.      S. Kebir, F. C. Gaertner, M. Mueller, M. Nelles, M. Simon, M. Stuplich, C. Schaub, M.

Niessen, F. Mack, R. A. Bundschuh, S. Greschus, M. Essler, M. Glass, U. Herrlinger: 18F-

fluorethyl-L-tyrosin Positron Emission Tomography for the Differential Diagnosis of Tumefactive

Multiple Sclerosis Versus Glioma: A Case Report. Oncol. Lett., 11(3): 2195-2198, 2016.

Befundabfrage

Mo. - Fr.: 08:00 Uhr - 16:00 Uhr

Tel.: +49 (0)228 / 287 - 11089

Fax: +49 (0) 228 / 287-16615

anmeldungnuklearmedizin@ukbonn.de

Terminvergabe


Bitte vereinbaren Sie telefonisch einen Termin.

Schilddrüsenambulanz:
Tel.: +49 (0) 228 / 287-16171

Fax: +49 (0) 228 / 287-19179

PET/CT:
Tel.: +49 (0) 228 / 287 - 11088
Fax: +49 (0) 228 / 287-16207

Konventionelle Szintigraphie:
Tel.: +49 (0) 228 / 287-16171

Therapie-Sekretariat:
Tel.: +49 (0) 228 / 287-16974

Fax: +49 (0) 228 / 287-19057

Therapiestation Winkler:
Tel.: +49 (0) 228 / 287-16855
Fax: +49 (0) 228 / 287-19107

 

Oberarztsekretariat: S. Döbeling

Tel.: 0228 / 287 - 16181

Fax: 0228 / 287 - 19057

 

Die Anmeldung erfolgt im Haus 21 (Nuklearmedizin)

 

Klinik und Poliklinik für Nuklearmedizin

Universitätsklinikum Bonn

Venusberg-Campus 1

Gebäude 21

53127 Bonn

 

Lageplan_DINA4_2019-04-01_QRC.pdf
Adobe Acrobat Dokument 655.0 KB